The report titled August 2024 Pharmaceutical Industry Foreign Trade Analysis (Ağustos 2024 İlaç Endüstrisi Dış Ticaret Analizi), published by Pharmaceutical Industry Employers’ Association of Türkiye, provides a detailed analysis of Türkiye’s foreign trade, focusing particularly on the pharmaceutical industry. This “August 2024 Pharmaceutical Industry Foreign Trade Analysis” offers key insights into the performance and dynamics of Türkiyes’s pharmaceutical foreign trade within the context of its overall trade landscape.
Over a 12-month period, Türkiye’s total exports increased by 3.5% compared to the previous period, reaching $261.8 billion.
The report specifically highlights the performance of the pharmaceutical industry in foreign trade. Here are a few key metrics:
Import and Export Dynamics: The report likely includes an analysis of both import and export trends within the pharmaceutical sector, providing insights into the industry’s trade balance and key markets.
Export Performance: The pharmaceutical industry’s export figures are analysed in detail. In the first eight months of 2024, Türkiye’s pharmaceutical exports rose by 4.3% to 1.4907 billion USD, while imports increased by 4.9% to 3.9891 billion USD, resulting in a trade deficit of 2.4984 billion USD and a coverage ratio of 37.4%. Over 12 months, pharmaceutical exports grew by 4.4% to 2.29 billion USD, and imports rose by 5.8% to 5.9 billion USD, leading to a 3.6 billion USD trade deficit and a 38.6% coverage ratio.
The report includes an analysis of the main markets for Turkish pharmaceutical exports and imports, as well as the types of pharmaceutical products that are most traded. As of August 2024, South Korea, Hungary, and Iraq are the top three destinations for pharmaceutical exports from Türkiye, with Asia accounting for 45.3% of the export market. During the same period, 63.2% of pharmaceutical imports to Türkiye came from Europe, with the United States, Germany, and Ireland being the top three import sources.
The analysis might be set against the broader economic and policy context, including any government initiatives or global economic conditions that affect the pharmaceutical industry’s trade activities. A more detailed report discussing changes in market trends, regulatory impacts, and other factors influencing the pharmaceutical industry’s foreign trade would be beneficial for fully understanding the current situation of the pharmaceutical industry in Türkiye.
To fully grasp the insights presented within this “August 2024 Pharmaceutical Industry Foreign Trade Analysis,” it would be necessary to read the complete report, as the summary provided does not include all the specific details and data points covered in the analysis.
🚀 Understand the market dynamics of Novo Nordisk’s GLP-1 Market Share Decline.
A case of demand underestimation, supply chain strain, and competitor agility. Using systems thinking, we unpack the dynamic forces behind Eli Lilly’s surge—and what strategic levers pharma leaders must pull to stay ahead.
#SyenzaNews #PharmaStrategy #MarketDynamics #NovoNordisk #EliLilly #GLP1
💡 Can tolebrutinib reshape the treatment landscape for progressive multiple sclerosis?
A recent report from the Institute for Clinical and Economic Review reveals promising insights on tolebrutinib, demonstrating a 31% reduction in disability progression for patients with non-relapsing secondary progressive MS. Yet, mixed outcomes and potential safety concerns raise critical questions about its long-term efficacy and market access.
Explore the nuances of this groundbreaking therapy and its implications for healthcare economics.
#SyenzaNews #HealthEconomics #MarketAccess
🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?
This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.
Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!
#SyenzaNews #HealthEconomics #Innovation #MarketAccess
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
